Biotricity Inc (BTCY)
OTHER OTC:BTCY
Want to see BTCY full AI Analyst Report?
BTCY Stock Chart & Stats
$0.30
-$0.09(-17.87%)
At close: 4:00 PM EST
$0.30
-$0.09(-17.87%)
Day’s Range― - ―
52-Week Range$0.10 - $0.75
Previous CloseN/A
Volume50.15K
Average Volume (3M)43.96K
Market Cap
$1.89M
Enterprise Value$30.66M
Total Cash (Recent Filing)$256.36K
Total Debt (Recent Filing)$27.09M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding14,956,914
10 Day Avg. Volume84,984
30 Day Avg. Volume43,962
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.53
P/FCF Ratio-3.07
Enterprise Value/Market Cap16.23
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit2.45
Enterprise Value/Ebitda114.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross MarginGross margin expanded to 80.4% driven by an 84% subscription mix that captures the scale benefits of fixed cloud-hosting and cellular data contracts.
Patent AcquisitionPatent acquisition enhances Biotricity’s competitive profile in multi-sensor monitoring.
Product InnovationProduct innovation remains a catalyst as the next-generation, cellular-enabled Biocore Pro gains traction, and strategic partnerships extend Biotricity’s remote monitoring algorithms into new markets.
Bears Say
Neutral RatingWhile there is stable growth and a bullish outlook, a Neutral rating is maintained as expansion consistency, initiative outcomes, and respective financial impact are monitored.
Small-Cap RisksAn investment in Biotricity is subject to the risks inherent in all small-cap companies, including dilution, end-market product acceptance and pricing, and competition against companies with greater resources.
Biotricity News
BTCY FAQ
What was Biotricity Inc’s price range in the past 12 months?
Biotricity Inc lowest stock price was $0.10 and its highest was $0.75 in the past 12 months.
What is Biotricity Inc’s market cap?
Biotricity Inc’s market cap is $1.89M.
When is Biotricity Inc’s upcoming earnings report date?
Biotricity Inc’s upcoming earnings report date is Aug 17, 2026 which is in 50 days.
How were Biotricity Inc’s earnings last quarter?
Currently, no data Available
Is Biotricity Inc overvalued?
According to Wall Street analysts Biotricity Inc’s price is currently Overvalued.
Does Biotricity Inc pay dividends?
Biotricity Inc does not currently pay dividends.
What is Biotricity Inc’s EPS estimate?
Biotricity Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biotricity Inc have?
Biotricity Inc has 14,956,914 shares outstanding.
What happened to Biotricity Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biotricity Inc?
Currently, no hedge funds are holding shares in BTCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biotricity Inc
Headquartered in Redwood City, California, Biotricity, Inc. is a medical technology enterprise delivering biometric data monitoring solutions, primarily within the United States. The company's efforts are dedicated to supplying remote monitoring capabilities to the medical, healthcare, and individual consumer markets, encompassing both diagnostic tools and ongoing management support for chronic and lifestyle-related conditions. Among its key offerings are the Bioflux mobile cardiac telemetry solution, an integrated ECG device, alongside specialized ECG analysis software designed to process and synthesize patient heart rhythm data, complemented by various software components.
BTCY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: double-digit revenue growth, meaningful gross margin expansion (+516 bps), consecutive positive EBITDA quarters (3) and six consecutive quarters of positive free cash flow, plus strong digital user and provider network expansion. Remaining challenges include a continued net loss ($1.1M), modest absolute revenue scale ($4.0M quarterly), concentration of revenue in technology fees (91.2%), and dependence on future FDA/regulatory clearances and large-account sales cycles. Overall, the positives (margin improvement, recurring revenue, cash-flow and EBITDA momentum, product traction and distribution reach) outweigh the remaining execution and scale risks.View all BTCY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.45% Other Institutional Investors
99.55% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---